Alliance for Lupus Research & Pfizer's Centers for Therapeutic Innovation: Challenge Grant Program

The ALR and Pfizer are accepting applications to support research that facilitates and accelerates development of new therapies for lupus patients. Awards are intended for studies of high scientific merit and translational potential focused on the role of interferon-beta in the pathogenesis and/or maintenance of SLE. Award amount is up to $150,000 per year for two years. Application deadline is April 1 by 5 p.m.

The Office of Corporate and Foundation Relations has identified the following private funding opportunity:

Alliance for Lupus Research & Pfizer's Centers for Therapeutic Innovation: Challenge Grant Program
http://www.lupusresearch.org

ALR and Pfizer are collaborating to support research that investigates the expression and function of IFN- β and/or related gene products in blood and tissue samples from SLE patients and other interferonopathies including rare autoimmune diseases; and/or (2) informs development of therapeutic approaches that target IFN- β by identifying novel ways to stratify patients; and/or (3) characterizes the regulation and unique functional properties of IFN- β. Investigators with doctoral degrees (MD, PhD, DO or equivalent) are eligible to apply. Scientific independence, as evidenced by direction of a research program, a publication record, or other experience that establishes scientific leadership is necessary to apply.

Application Deadline: April 1, 2016 by 5:00pm EST. Application Guideline for the award.

The UNC Office of Corporate and Foundation Relations is available to provide assistance in pursuing privately funded opportunities. Email cfr@unc.edu or phone (919) 962-3423. 

Filed under: